Quality of life in children and adolescents with drug-resistant epilepsy: a single-center study in Lima, Peru
DOI:
https://doi.org/10.59594/iicqp.2026.v4n1.148Keywords:
Drug Resistant Epilepsy, Quality of Life, Child, AdolescentAbstract
Objective: To describe the quality of life and identify its associated clinical and epidemiological factors in children and adolescents with drug-resistant epilepsy treated at a national referral center in Lima, Peru.
Methods: A cross-sectional, single-center study was conducted, including patients younger than 18 years with a diagnosis of drug-resistant epilepsy, treated either on an outpatient basis or hospitalized. Quality of life was measured using the Quality of Life in Childhood Epilepsy Questionnaire (QOLCE), reported by their primary caregivers. Associations between clinical and sociodemographic variables and quality of life were evaluated using linear regression.
Results: A total of 102 patients were included in the study. The mean quality-of-life score was 33.9 points, close to the minimum value of the QOLCE. In both the bivariate and multivariate models, older patient age (βa = -0.87; 95% CI: -1.60 to -0.12; p = 0.021), residing outside the capital (βa = -9.00; 95% CI: -13.00 to -4.80; p < 0.001), not attending school (βa = -14.00; 95% CI: -18.00 to -9.00; p < 0.001), having intellectual disability (βa = -16.00; 95% CI: -23.00 to -8.50; p < 0.001), and having total or partial caregiver dependence (βa = -12.00; 95% CI: -20.00 to -5.20; p < 0.001) were associated with lower quality of life.
Conclusions: In this group of children and adolescents with drug-resistant epilepsy, a low quality of life was observed. Older patient age, residing outside the capital, not attending school, having intellectual disability, and having total or partial caregiver dependence were associated with lower quality of life.
Downloads
References
1. Strzelczyk A, Griebel C, Lux W, Rosenow F, Reese JP. The Burden of Severely Drug-Refractory Epilepsy: A Comparative Longitudinal Evaluation of Mortality, Morbidity, Resource Use, and Cost Using German Health Insurance Data. Front Neurol. 2017;8:712. doi: 10.3389/fneur.2017.00712
2. Kwan P, Sander JW. The natural history of epilepsy: an epidemiological view. J Neurol Neurosurg Psychiatry. 2004;75(10):1376-81. doi: 10.1136/jnnp.2004.045690
3. Fiest KM, Sauro KM, Wiebe S, Patten SB, Kwon CS, Dykeman J, et al. Prevalence and incidence of epilepsy: A systematic review and meta-analysis of international studies. Neurology. 2017;88(3):296-303. doi: 10.1212/WNL.0000000000003509
4. Ngugi AK, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia. 2010;51(5):883-90. doi: 10.1111/j.1528-1167.2009.02481.x
5. GBD Epilepsy Collaborators. Global, regional, and national burden of epilepsy, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Public Health. 2025;10(3):e203-27. doi: 10.1016/S2468-2667(24)00302-5
6. Biset G, Abebaw N, Gebeyehu NA, Estifanos N, Birrie E, Tegegne KD. Prevalence, incidence, and trends of epilepsy among children and adolescents in Africa: a systematic review and meta-analysis. BMC Public Health. 2024;24:771. doi: 10.1186/s12889-024-18236-z
7. Patel M, Goel AD, Saini L, Kaushal R, Mathur D, Mittal AK, et al. Prevalence of pediatric and adolescent epilepsy in India: A systematic review and meta-analysis. Seizure. 2025;127:36-43. doi: 10.1016/j.seizure.2025.02.012
8. Laxer KD, Trinka E, Hirsch LJ, Cendes F, Langfitt J, Delanty N, et al. The consequences of refractory epilepsy and its treatment. Epilepsy Behav. 2014;37:59-70. doi: 10.1016/j.yebeh.2014.05.031
9. Sultana B, Panzini MA, Veilleux Carpentier A, Comtois J, Rioux B, Gore G, et al. Incidence and Prevalence of Drug-Resistant Epilepsy: A Systematic Review and Meta-analysis. Neurology. 2021;96(17):805-17. doi: 10.1212/WNL.0000000000011839
10. Giussani G, Canelli V, Bianchi E, Franchi C, Nobili A, Erba G, et al. A population-based study of active and drug-resistant epilepsies in Northern Italy. Epilepsy Behav. 2016;55:30-7. doi: 10.1016/j.yebeh.2015.11.021
11. Kalilani L, Sun X, Pelgrims B, Noack-Rink M, Villanueva V. The epidemiology of drug-resistant epilepsy: A systematic review and meta-analysis. Epilepsia. 2018;59(12):2179-93. doi: 10.1111/epi.14596
12. Kim H, Thurman DJ, Durgin T, Faught E, Helmers S. Estimating Epilepsy Incidence and Prevalence in the US Pediatric Population Using Nationwide Health Insurance Claims Data. J Child Neurol. 2016;31(6):743-9. doi: 10.1177/0883073815620676
13. McCagh J, Fisk JE, Baker GA. Epilepsy, psychosocial and cognitive functioning. Epilepsy Res. 2009;86(1):1-14. doi: 10.1016/j.eplepsyres.2009.04.007
14. Berg AT, Nickels K, Wirrell EC, Geerts AT, Callenbach PMC, Arts WF, et al. Mortality Risks in New-Onset Childhood Epilepsy. Pediatrics. 2013;132(1):124-31. doi: 10.1542/peds.2012-3998
15. Harden CL, Maroof DA, Nikolov B, Fowler K, Sperling M, Liporace J, et al. The effect of seizure severity on quality of life in epilepsy. Epilepsy Behav. 2007;11(2):208-11. doi: 10.1016/j.yebeh.2007.05.002
16. Liu C, Hu Y, Zhou J, Guan Y, Wang M, Qi X, et al. Retrospective Clinical Analysis of Epilepsy Treatment for Children with Drug-Resistant Epilepsy (A Single-Center Experience). Brain Sci. 2023;13(1):14. doi: 10.3390/brainsci13010014
17. Kahane P, Berg A, Löscher W, Nordli D, Perucca E. Drug-resistant epilepsies. Montrouge: John Libbey Eurotext; 2008.
18. Aneja S, Jain P. Refractory epilepsy in children. Indian J Pediatr. 2014;81(10):1063-72. doi: 10.1007/s12098-014-1533-1
19. Love CE, Webbe F, Kim G, Lee KH, Westerveld M, Salinas CM. The role of executive functioning in quality of life in pediatric intractable epilepsy. Epilepsy Behav. 2016;64(Pt A):37-43. doi: 10.1016/j.yebeh.2016.08.018
20. Sabaz M, Cairns DR, Lawson JA, Bleasel AF, Bye AM. The health-related quality of life of children with refractory epilepsy: a comparison of those with and without intellectual disability. Epilepsia. 2001;42(5):621-8. doi: 10.1046/j.1528-1157.2001.25200.x
21. Jain P, Subendran J, Smith ML, Widjaja E, PEPSQOL Study Team. Care-related quality of life in caregivers of children with drug-resistant epilepsy. J Neurol. 2018;265(10):2221-30. doi: 10.1007/s00415-018-8979-4
22. Altwaijri WA, Yahya BJ, Alasmari LB, Alsultan RN, Alsuhaibani SM, Alsemih RM, et al. Quality of life in paediatrics with intractable epilepsy in a large paediatric university hospital in Riyadh, Saudi Arabia. J Family Med Prim Care. 2020;9(11):5523-36. doi: 10.4103/jfmpc.jfmpc_1172_20
23. Katchanov J, Birbeck GL. Epilepsy care guidelines for low- and middle- income countries: From WHO mental health GAP to national programs. BMC Med. 2012;10:107. doi: 10.1186/1741-7015-10-107
24. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069-77. doi: 10.1111/j.1528-1167.2009.02397.x
25. Sabaz M, Cairns DR, Lawson JA, Nheu N, Bleasel AF, Bye AM. Validation of a new quality of life measure for children with epilepsy. Epilepsia. 2000;41(6):765-74. doi: 10.1111/j.1528-1157.2000.tb00240.x
26. Ibáñez-Micó S, Velandrino-Nicolás A, Gómez-Conesa A. Spanish translation, cross-cultural adaptation, and initial assessment of psychometric properties of the Life in Childhood Epilepsy Questionnaire (QOLCE-16). Epilepsy Behav. 2022;134:108838. doi: 10.1016/j.yebeh.2022.108838
27. Conway L, Smith ML, Ferro MA, Speechley KN, Connoly MB, Snead OC, et al. Correlates of health-related quality of life in children with drug resistant epilepsy. Epilepsia. 2016;57(8):1256-64. doi: 10.1111/epi.13441
28. Rojulpote KV, Smith ML, Puka K, Speechley KN, Ferro MA, Connolly MB, et al. Pre-Operative Predictors of Health-Related Quality of Life Two Years After Pediatric Epilepsy Surgery: A Prospective Cohort Study. Seizure. 2023;111:196-202. doi: 10.1016/j.seizure.2023.08.016
29. Phillips NL, Widjaja E, Smith ML. Family resources moderate the relationship between seizure control and health-related quality of life in children with drug-resistant epilepsy. Epilepsia. 2020;61(8):1638-48. doi: 10.1111/epi.16602
30. Pesantes MA, Moyano LM, Sommerville C, Cysticercosis Working Group in Peru and COHESION Project. Neurocysticercosis in Northern Peru: Qualitative Insights from men and women about living with seizures. PLoS Negl Trop Dis. 2020;14(10):e0008715. doi: 10.1371/journal.pntd.0008715
31. Pacheco-Barrios K, Navarro-Flores A, Cardenas-Rojas A, de Melo PS, Uygur-Kucukseymen E, Alva-Diaz C, et al. Burden of epilepsy in Latin America and The Caribbean: a trend analysis of the Global Burden of Disease Study 1990 - 2019. Lancet Reg Health Am. 2022;8:100140. doi: 10.1016/j.lana.2021.100140
32. Cueto S, Rojas V, Dammert M, Felipe C. Cobertura, oportunidades y percepciones sobre la educación inclusiva en el Perú. Documento de Investigación 87 [Internet]. Lima: GRADE; 2018 [citado 16 de diciembre de 2025]. Disponible en: https://grade.org.pe/publicaciones/cobertura-oportunidades-y-percepciones-sobre-la-educacion-inclusiva-en-el-peru/
33. Hixson JD, Kirsch HE. The effects of epilepsy and its treatments on affect and emotion. Neurocase. 2009;15(3):206-16. doi: 10.1080/13554790802632876
34. Lothman DJ, Pianta RC. Role of child-mother interaction in predicting competence of children with epilepsy. Epilepsia. 1993;34(4):658-69. doi: 10.1111/j.1528-1157.1993.tb00443.x
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Investigación e Innovación Clínica y Quirúrgica Pediátrica
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
This website is published under the 
